January 27, 2015 9:56 AM ET


Company Overview of Amsterdam Molecular Therapeutics (AMT) Holding N.V.

Company Overview

Amsterdam Molecular Therapeutics (AMT) Holding N.V. develops human gene based therapies primarily in the Netherlands. Amsterdam Molecular Therapeutics (AMT) Holding N.V. was formerly known as Amsterdam Molecular Therapeutics (AMT) Holding B.V. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands. Amsterdam Molecular Therapeutics (AMT) Holding N.V. is in the process of liquidation of its remaining assets

Meibergdreef 61

Amsterdam Zuidoost

Amsterdam,  1105 BA


Founded in 1998

85 Employees


31 20 566 7394


31 20 566 9272

Key Executives for Amsterdam Molecular Therapeutics (AMT) Holding N.V.

Amsterdam Molecular Therapeutics (AMT) Holding N.V. does not have any Key Executives recorded.

Similar Private Companies By Industry

Company Name Region
Protix Biosystems BV Europe
Mart Microbiology B.V. Europe
Biomade Europe
Progentix Orthobiology B.V. Europe
SkylineDx B.V. Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Amsterdam Molecular Therapeutics (AMT) Holding N.V., please visit www.amtbiopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.